Background
Breast cancer (BC), as one of the most frequently diagnosed cancer types in women, accounts for approximately 29% of all female malignancy cases [
1,
2]. Although clinical advances, such as mastectomy, radiotherapy, chemotherapy and even systemic treatment have been achieved in decades, the 5-year overall survival of BC patients is still poorer than anticipation, especially in metastasis cases [
3]. Despite an array of gene-expression signatures have been discovered as diagnostic and treatment biomarkers in BC, the molecular function of long non-coding RNAs (lncRNAs) in this field remains on the initial research period. Exploring the mechanism of lncRNA in the pathological processes of BC is of vital importance for future practical target prognosis.
LncRNAs, with over 200 nucleotides in length, belong to a category of RNAs that lack the ability to encode proteins [
4]. They have been manifested to participate in various biological activities, such as proliferation, differentiation, transcriptional modification, apoptosis, cell invasion and migration [
5‐
9]. Furthermore, lncRNAs have emerged as novel focuses of clinical applications, since they play pivotal role in human malignancies [
10‐
12].
The prevalent ceRNA mechanism has proofed that lncRNAs can function as competing endogenous RNAs (ceRNAs) for their interaction with sequestered microRNAs (miRNAs), resulting in elevated expression of downstream target genes [
13]. In BC, previous studies have found that some lncRNAs were dysregulated and predicted clinical prognosis. For instance, RHPN1-AS1 was found as abnormally up-regulated in BC and facilitated malignant phenotypes in vitro [
14]. In addition, Li et al. [
15] discovered that lncRNA HOXC13-AS, which was significantly up-regulated in BC, enhanced cell proliferation ability through up-regulating PTEN expression via suppressing miR-497-5p.
Previous studies have revealed the aberrant elevation of FLVCR1-AS1 in several tumors via being engaged in the lncRNA-miRNA-mRNA ceRNA network. For example, in gastric cancer (GC), enriched FLVCR1-AS1 promoted malignant behaviors of GC cells by its ceRNA role of c-Myc through targeting miR-155. Besides, FLVCR1-AS1 overexpression tended to result in poor prognostic outcomes in GC cases [
16]. FLVCR1-AS1 contributed to cellular activities in glioma through targeting miR-4731-5p/E2F2 signaling [
17]. Also, FLVCR1-AS1 facilitated biological behaviors of ovarian cancer cells via regulating miR-513/YAP1 signaling [
18]. FLVCR1-AS1 sponged miR-485-5p to modulate biological behaviors in human cholangiocarcinoma [
19]. However, the expression profile, specific function and acting mechanism of FLVCR1-AS1 in BC have not been elucidated yet. Hence, present study aimed to investigate whether and how FLVCR1-AS1 functions in BC.
Methods
Cell culture
Human normal breast epithelial cell (MCF-10A) and BC cells (MDA-MB-231, T47D, BT-474, SKBR3, MCF7) were bought from Chinese Academy of Sciences (Beijing, China). Cells were grown in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Invitrogen) and 1% penicillin/streptomycin (Sigma-Aldrich, Milan, Italy) with 5% CO2 at 37 °C. LiCL (Taili industrial co. LTD, Shanghai, China), the Wnt/β-catenin pathway activator, was added into culture medium for treating SKBR3 and MCF7 cells.
Cell transfection
SKBR3 and MCF7 cells were transfected with specific shRNAs against FLVCR1 (sh-FLVCR1-AS1#1#2), MYC (sh-MYC) and negative control (shCtrl), as well as pcDNA3.1/CTNNB1, pcDNA3.1/MYC and the empty pcDNA3.1 vector (all purchased from GenePharma, Shanghai, China), separately. The miR-381-3p mimics, miR-381-3p inhibitor, NC mimics and NC inhibitor were simultaneously constructed by GenePharma. Transfection was conducted for 48 h in light of the protocol of Lipofectamine2000 (Invitrogen)
qRT-PCR
TRIzol reagent (Takara, Otsu, Japan) was used for extracting total RNA from SKBR3 or MCF7 cells. Subsequently, total RNAs were reversely transcribed into cDNAs under Reverse Transcription Kit (Takara). The qRT-PCR was performed with utilization of SYBR Green real-time PCR Kit (Takara) on the Bio-Rad CFX96 system (Bio-Rad, Hercules, CA). Fold expression changes were calculated via 2−ΔΔCt method, with GAPDH/U6 as reference gene.
Cell counting kit-8 (CCK-8) assay
Cells (1 × 104) in 96-well plates were cultured with10 µL CCK-8 reagent over specific time points. Absorbance was evaluated at 450 nm using a microplate reader (Bio-Tek Instruments, Hopkinton, MA, USA).
1 × 103 cells were cultured in 6-well plates for 2 weeks. After fixed in methanol (Solarbio, Beijing, China), colonies were processed with crystal violet (Sigma-Aldrich). Visible colonies were counted manually under microscope (Olympus, Tokyo, Japan).
TUNEL assay
TUNEL staining assay was performed using In Situ Cell Death Detection Kit (Roche, Mannheim, Germany). Following nuclei staining with DAPI (Sigma-Aldrich), relative fluorescence intensity was determined via EVOS FL microscope (Olympus).
Transwell assay
2 × 104 cells in the top compartment were added with serum-free medium, while medium containing 10% FBS was placed into bottom chamber. After 48 h, migrated cells were fixed with paraformaldehyde (Solarbio) and dyed in crystal violet solution. Invasion assay was performed using the upper chamber was pre-coated with Matrigel (BD Biosciences, Shanghai, China). The number of migrated or invaded cells was captured via a microscope (Olympus).
Western blot
Total protein was obtained from cells which were lysed by RIPA lysis buffer. Protein concentration was measured with BCA Kit (Pierce, Appleton, WI, USA). We isolated proteins with SDS-PAGE, which were moved to PVDF membranes. 5% skimmed milk was used for blocking membranes, and then were co-cultured with primary antibodies for p53 (ab32389), Bax (ab32503), Bcl-2 (ab185002), MMP2 (ab215986), MMP7 (ab205525), AKT (ab179463), p-AKT (ab38449), β-catenin (ab32572), p65 (ab16502), p-p65 (ab6503) and GAPDH (ab8245) from Abcam (Cambridge, USA). GAPDH was used as internal control. Secondary antibodies were added to incubate for 1 h. Amount of proteins was examined via chemiluminescence detection system. IMAGEJ software (National Institutes of Health, Bethesda, Maryland, USA) was utilized to quantify protein bands, with GAPDH as normalized control.
Chromatin immunoprecipitation (ChIP)
ChIP experiment was processed with usage of Magna ChIP Kit (Millipore, Darmstadt, Germany). After cross-linked chromatin was sonicated to 200–300-bp fragments by ultrasound, lysates were immunoprecipitated with anti-MYC or anti-IgG. Precipitated chromatin DNA was detected by RT-qPCR.
Luciferase reporter assay
For FLVCR1-AS1 promoter analysis, the pGL3-Basis reporter (Promega, Madison, WI, USA) vector containing FLVCR1-AS1 promoter was co-transfected with pcDNA3.1/MYC and empty pcDNA3.1 vector, or shCtrl and sh-MYC into cells. The wild-type (WT) and mutant (Mut) binding sites of miR-381-3p mimics in FLVCR1-AS1 sequence or CTNNB1 3′UTR was sub-cloned into pmirGLO dual-luciferase vector (Promega) to construct FLVCR1-AS1-WT/Mut or CTNNB1-WT/Mut, then co-transfected with miR-381-3p mimics or NC mimics into cells. To conduct TOP/FOP-Flash analysis, TOP/FOP-Flash (Genechem) was co-transfected into SKBR3 and MCF7 cells along with sh-FLVCR1-AS1#1 or shCtrl. The luciferase activity was lastly determined via Dual-Luciferase Reporter Assay System (Promega).
MTT assay
1 × 103 cells in 96-well plates were mixed with 20 µL MTT reagents over 24, 48,72 and 96 h. Later, dimethyl sulfoxide (DMSO) was added. The optical density at 490 nm was analyzed by micro-plate reader (Bio-Tek Instruments, Hopkinton, MA, USA).
Subcellular fractionation
Subcellular isolation of RNAs in SKBR3 and MCF7 cells was performed by Cytoplasmic and Nuclear RNA Purification Kit (Norgenbiotek Corporation, Thorold, ON, Canada), followed by fraction analysis via qRT-PCR.
Fluorescence in situ hybridization (FISH) Assay
Fluorescence-conjugated FLVCR1-AS1 probes were produced by Bersinbio Company (Guangzhou, China). BC cells in paraformaldehyde were dehydrated with ethanol. Air-dried cells were denatured for incubation with FISH probes utilizing hybridization reaction buffer overnight. After washing by ×2 saline-sodium citrate, cells were dyed in Hoechst and the results were recorded by Zeiss LSM800 confocal laser microscopy (Zeiss, Oberkochen, Germany).
RNA pull down assay
The FLVCR1-AS1-WT, FLVCR1-AS1-Mut and NC were biotin labeled into Biotin FLVCR1-AS1 WT, Biotin FLVCR1-AS1 Mut and Biotin Ctrl, severally. Then, cell lysates were cultured with the biotinylated probe and M-280 streptavidin magnetic beads (Sigma-Aldrich). The miR-381-3p levels were analyzed by qRT-PCR.
RNA immunoprecipitation (RIP)
RNA-binding protein immunoprecipitation kit (Millipore) was applied for performing the RIP assay. SKBR3 and MCF7 cells were lysed with lysis buffer and then incubated with anti-Ago2 and negative control anti-IgG. RNA enrichment was analyzed by qRT-PCR.
TUNEL assay
The apoptosis of SKBR3 and MCF7 cells were studied via TUNEL Apoptosis Kit (Invitrogen), with employment of DAPI (Koritai Biotechnology, Beijing, China) for dying. Cells were then observed and captured by fluorescence microscopy (Olympus, Tokyo, Japan).
Tumor growth in nude mice
Male nude mice were obtained commercially from Shi Laike Company (Shanghi, China). Cells transfected with sh-FLVCR1-AS1#1 or shCtrl were injected subcutaneously into mice. Tumor volumes were recorded every 4 day. All mice were sacrificed after 4 weeks, and tumors were removed, weighed. Approval of this animal study was obtained from the Animal Research Ethics Committee of Minhang Hospital, Fudan University.
Statistical analysis
GraphPad Prism 7.0 software (La Jolla, CA, USA) was applied for statistical analysis. Results were manifested as mean ± SD. The difference of groups was compared via Student’s t test or one way ANOVA analysis. P < 0.05 indicated the statistical significance and all experiments were run in no less than triplicate.
Discussion
Despite rapid progression in the diagnosis and treatment and of BC, the mortality rate still remains a challenge that needs the determination of sensitive targets. To improve early diagnosis and therapeutic methods, identifying novel molecular targets for BC is becoming increasingly paramount. Accumulating studies have uncovered the crucial ceRNA roles of lncRNAs in the occurrence and development of a wide array of human diseases [
23‐
26]. Increasing reports have demonstrated that lncRNAs can play important regulatory role in many biological activities and are correlated with the carcinogenesis of cancers [
25]. Determining the relationship between lncRNAs and their downstream targets would contribute to the diagnosis and treatment of patients with BC.
In present study, we found that FLVCR1-AS1 was significantly up-regulated in BC cell lines. Knockdown of FLVCR1-AS1 sharply suppressed BC cell proliferation, migration and invasion, while stimulating cell apoptosis in vitro. Besides, the expression of FLVCR1-AS1 was found to be positively correlated with tumor growth, size and volume in vivo, which supported that FLVCR1-AS1 played an oncogenic role in BC. Besides, MYC transcriptionally activated FLVCR1-AS1 in BC.
MiR-381-3p was identified as a potential target gene of FLVCR1-AS1. MiR-381-3p has been discovered to be a tumor suppressor gene and reported to be down-regulated in various human malignancies, including cervical cancer, bladder cancer, oral squamous cell carcinoma as well as BC [
27‐
29]. We verified the interaction between miR-381-3p and cytoplasmic FLVCR1-AS1. Furthermore, miR-381-3p inhibition reversed the suppressing effects of sh-FLVCR1-AS1 on malignant behaviors of BC cells in vitro, which indicated that FLVCR1-AS1 exerted its oncogenic role in BC via sponging miR-381-3p.
We observed that only β-catenin associated with Wnt/β-catenin was significantly down-regulated after FLVCR1-AS1 knockdown. We observed that LiCl, as agonist of Wnt/β-catenin pathway, could abolish the anti-tumor effects of FLVCR1-AS1 knockdown. Subsequently, we identified that CTNNB1 was the target gene of miR-381-3p. Additionally, CTNNB1 has been extensively reported to play an oncogenic role and predicted poor prognosis in multiple cancers. In present study, we found that overexpression of CTNNB1 could abrogate the tumor-inhibiting ability of sh-FLVCR1-AS1. In other words, CTNNB1 up-regulation could rescue the anti-oncogenic function of FLVCR1-AS1 depletion. Together, our finding initially suggested that lncRNA FLVCR1-AS1 could function as miR-381-3p sponge and up-regulate the expression of CTNNB1 and activate Wnt/β-catenin pathway, consequently aggravating BC malignant progresses.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.